Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VML-0001
- Development stage
- Unknown
- Lead developer
- Viramal
- Administration
- Topical
01
Overview
VML-0001 is an investigational pharmaceutical agent developed by Viramal Limited for women's health indications. It has been studied in a completed Phase 1 clinical trial designed to evaluate its effects on vaginal pH in healthy post-menopausal women with vaginal atrophy. The exact mechanism of action, molecular target, and formulation remain undisclosed in public sources, although it is developed within a women's health pipeline that includes menopausal hormone therapy and sexual health therapeutics[1][3][7]. No drug approvals or further clinical indication data are available.
- Brand names
- VML-0001VML0001VML 0001
- Other names
- VML-0001VML0001VML 0001
Beyond the preview
Go deeper on VML-0001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VML-0001.